Robertson Morag, Liversidge Janet, Forrester John V, Dick Andrew D
Department of Ophthalmology, University of Aberdeen, Aberdeen, Scotland, United Kingdom.
Invest Ophthalmol Vis Sci. 2003 Jul;44(7):3034-41. doi: 10.1167/iovs.02-1156.
During experimental autoimmune uveoretinitis (EAU), infiltrating macrophages become activated to express nitric oxide synthase (NOS)-2 and generate nitric oxide (NO). The current study was designed to determine whether neutralizing TNF activity with a soluble fusion protein of TNFp55 receptor (sTNFr-IgG) inhibits macrophage activation, thereby contributing to reduced tissue damage observed with such treatment.
EAU was induced in Lewis rats by active immunization with soluble retinal extract (RE) and pertussis toxin (intraperitoneally), and animals were treated on days 6 and 8 after immunization with either sTNFr-IgG or human (hu)IgG. Disease course and severity were noted clinically, and eyes were enucleated for histologic scoring, including TUNEL immunofluorescence, at various stages of disease. Infiltrating retinal macrophages were isolated through a density gradient and subsequently phenotyped by flow cytometry, analyzed for ability to produce nitrite, either spontaneously or after cytokine stimulation, and assayed by PCR for cytokine gene expression.
Neutralizing TNF activity suppressed tissue damage without impeding myeloid cell infiltrate. Moreover, with sTNFr-IgG treatment, infiltrating macrophages demonstrated reduced nitrite production at the height of disease, and the level of apoptosis within the retina of both ED1(+) cells and resident cells was reduced. PCR analysis demonstrated a significant increase in TGF beta signal and absent or low TNF signal throughout the disease course after treatment with sTNFr-IgG.
sTNFr-IgG successfully suppresses retinal damage and impairs macrophage activation but not trafficking during EAU. sTNFr-IgG-mediated suppression of NO production results in reduced levels of apoptosis of inflammatory cells and reduction in photoreceptor damage.
在实验性自身免疫性葡萄膜视网膜炎(EAU)期间,浸润的巨噬细胞被激活以表达一氧化氮合酶(NOS)-2并产生一氧化氮(NO)。本研究旨在确定用TNFp55受体的可溶性融合蛋白(sTNFr-IgG)中和TNF活性是否会抑制巨噬细胞激活,从而有助于减少这种治疗中观察到的组织损伤。
通过用可溶性视网膜提取物(RE)和百日咳毒素(腹腔内)主动免疫在Lewis大鼠中诱导EAU,并且在免疫后第6天和第8天用sTNFr-IgG或人(hu)IgG治疗动物。临床记录疾病进程和严重程度,并在疾病的各个阶段摘除眼睛进行组织学评分,包括TUNEL免疫荧光。通过密度梯度分离浸润的视网膜巨噬细胞,随后通过流式细胞术进行表型分析,分析其自发或细胞因子刺激后产生亚硝酸盐的能力,并通过PCR检测细胞因子基因表达。
中和TNF活性可抑制组织损伤而不阻碍髓样细胞浸润。此外,用sTNFr-IgG治疗时,浸润的巨噬细胞在疾病高峰期亚硝酸盐产生减少,ED1(+)细胞和驻留细胞视网膜内的凋亡水平降低。PCR分析表明,用sTNFr-IgG治疗后,在整个疾病过程中TGFβ信号显著增加,而TNF信号缺失或较低。
sTNFr-IgG成功抑制视网膜损伤并损害巨噬细胞激活,但不影响EAU期间的细胞运输。sTNFr-IgG介导的NO产生抑制导致炎症细胞凋亡水平降低和光感受器损伤减少。